Liquid Biopsy Predicts Recurrence in HPV-Independent Head and Neck Cancer Months Before Imaging

MedXY Editorial Team•Mar 23, 2026•news

The following key findings represent the core clinical takeaways from the study:

Tumor-informed ctDNA detection showed a 97% sensitivity in the pre-surgical setting for patients with HPV-independent HNSCC.
Minimal Residual Disease (MRD) positivity within six weeks of completing adjuvant treatment was associated with a 7-fold increase in the risk of death.
In the surveillance setting, MRD positivity was associated with an 8-fold increase in recurrence risk, providing a median lead time of five months before clinical or radiologic detection.
Multivariable analysis confirmed that ctDNA status is an independent prognostic factor, even when accounting for established risk factors like margin status and extracapsular extension.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

The following key findings represent the core clinical takeaways from the study:

Tumor-informed ctDNA detection showed a 97% sensitivity in the pre-surgical setting for patients with HPV-independent HNSCC.
Minimal Residual Disease (MRD) positivity within six weeks of completing adjuvant treatment was associated with a 7-fold increase in the risk of death.
In the surveillance setting, MRD positivity was associated with an 8-fold increase in recurrence risk, providing a median lead time of five months before clinical or radiologic detection.
Multivariable analysis confirmed that ctDNA status is an independent prognostic factor, even when accounting for established risk factors like margin status and extracapsular extension.